PharmiWeb.com - Global Pharma News & Resources
27-Jul-2020

Esophageal Cancer Drugs Market to Surpass US$ 1,547.8 Million by 2027, Owing to Increasing R&D in Esophageal Cancer Drugs

Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Request Sample

According to Global Esophageal Cancer Drugs Market, by Therapy Type (Chemotherapy (Docetaxel, Irinotecan, Trifluridine and Tipiracil, Carboplatin and Paclitaxel, Cisplatin and 5-fluorouracil, and Cisplatin with Capecitabine), Targeted Drug Therapy (Trastuzumab and Ramucirumab), and Immunotherapy (Pembrolizumab)), by Disease Indication (Adenocarcinomas, Gastrointestinal Stromal Tumors, Carcinoid Tumors, Squamous Cell Carcinoma, and Others), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), published by Coherent Market Insights, the global esophageal cancer drugs market was valued at US$  765.2  million in 2018 and is projected to exhibit a CAGR of 8.2% over the forecast period (2019 – 2027).

*The Download PDF brochure only consist of Table of Content, Research Framework, and Research Methodology.

Request PDF Research Report Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/3036

Increasing R&D in esophageal cancer drugs is expected to propel growth of the global esophageal cancer drugs market over the forecast period. For instance, in November 2018, Merck & Co., Inc. revealed the results of phase 3 clinical trial of Keytruda (pembrolizumab), which indicates Keytruda reduced the risk of death compared to chemotherapy in patients with squamous cell carcinoma or adenocarcinoma. Similarly, in 2018, Bristol-Meyer Squibb’s Opdivo (Nivolumab) intravenous infusion injection and Yervoy Injection is in the phase III clinical trial for the treatment of stomach cancer.

Moreover, approval and launch of new drugs is also expected to aid in growth of the market. For instance, in April 2014, the U.S. FDA approved Cyramza (ramucirumab) for use in combination with paclitaxel for the treatment of patients with advanced gastric or gastro-esophageal junction adenocarcinoma.

To know the latest trends and insights related to Esophageal Cancer Drugs market Press Release, click the link below: https://www.coherentmarketinsights.com/press-release/esophageal-cancer-drugs-market-to-surpass-us-15478-million-by-2027-2491

The global esophageal cancer drugs market is expected to witness a CAGR of 8.2% during the forecast period (2019–2027)

Among therapy type, the immunotherapy segment is expected to account for maximum share over the forecast period, owing to approval and launch of novel immunotherapies. For instance, in 2017, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda) for the treatment of gastroesophageal cancer in patients whose previous treatment did not work or stopped working.

Key Takeaways:

Increasing R&D in esophageal cancer drugs is expected to propel growth of the global esophageal cancer drugs market over the forecast period.

Apply Promo Code “CMIFIRST1000” And Get Instant Discount Of USD 1000
Buy Now This Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/3036

Major players operating in the global esophageal cancer drugs market include Amgen Inc., Eli Lilly and Company, F. Hoffmann-La Roche, Bristol-Myers Squibb Company, Boehringer Ingelheim GmbH, Bristol-Myers Squibb, GlaxoSmithKline Plc., Novartis AG, Johnson & Johnson, Gilead Sciences, Genentech, Inc., Sanofi-Aventis, and Merck & Co.

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website – www.coherentmarketinsights.com

Contact:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837

This content has been distributed via CDN Newswire press release distribution service. For press release enquires please mail us at contact@cdnnewswire.com.

Editor Details

  • Company:
    • CDN Newswire
Last Updated: 27-Jul-2020